Ranking antidepressants - Authors' reply

The Lancet

Volumn 373, Issue 9677, 2009, Pages 1761-1762

  Cipriani, Andrea ^a,b   Geddes, John R ^b   Furukawa, Toshiaki A ^c   Salanti, Georgia ^d   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; REBOXETINE; SERTRALINE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG TOLERABILITY; HUMAN; LETTER; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PUBLISHING; SYSTEMATIC ERROR; META ANALYSIS; NOTE; RISK; SAFETY; STANDARD; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; HUMANS; META-ANALYSIS AS TOPIC; ODDS RATIO; RESEARCH DESIGN; RISK; SAFETY; TREATMENT OUTCOME;

EID: 65649086116     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60979-X     Document Type: Letter

References (3)

1. Bekelman J.E., Li Y., and Gross P.C. Scope and impact of financial conflict of interest in biomedical research: a systematic review. JAMA 289 (2003) 454-465
2. Gartlehner G., Gaynes B.N., Hansen R.A., et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 149 (2008) 734-750
3. Mojtabai R., and Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. J Clin Psychiatry 69 (2008) 1064-1074